Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor regimens for post-transplant AML patients with molecular relapse after failure of first-line preemptive therapy
ChiCTR2300077634Phase 4Recruiting
- Sponsor
- Tongji Hospital
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of selinexor in acute myeloid leukemia (AML), sponsored by Tongji Hospital. Primary endpoint: MRD negative rate. Started Nov 2023; status: recruiting.
02
Drugs
selinexor
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2300077634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300077634.